INITIATION OF CELL INFECTION WITH EPSTEIN-BARR VIRUS

用 Epstein-Barr 病毒启动细胞感染

基本信息

  • 批准号:
    3130466
  • 负责人:
  • 金额:
    $ 6.45万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1984
  • 资助国家:
    美国
  • 起止时间:
    1984-01-01 至 1992-12-31
  • 项目状态:
    已结题

项目摘要

Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus that causes infectious mononucleosis, is associated with Burkitt's lymphoma and has been implicated in the etiology of nasopharyngeal carcinoma. It contributes to the development of lymphoproliferative syndromes and is thought to influence the pathogenesis of the human immunodeficiency virus. Recruitment of normal cells by endogenous virus, produced in increased amounts during episodes of immunosuppression, is of great relevance to virus induced pathology and probably contributes to development of the premalignant state. The overall objective of this proposal is to understand how EBV enters its two targets, the B lymphocyte and the epithelial cell and is based on the premise that clarification of how this process occurs is critical to rational design of chemical and biologic inhibitors of disease. Work in the previous award period implicated one of the virus envelope glycoproteins, gp85, in fusion of EBV with the lymphocyte membrane and provided evidence for additional novel proteins that may contribute to early events in infection. The goals of the current proposal are to continue study of virus entry and the envelope proteins involved in the process, to delineate functional domains of glycoprotein gp85, and to test the hypothesis that gp85 is a virus fusion protein. There are three specific aims. The first is to determine the function and structure/function relationships of gp85. A panel of monoclonal antibodies will be mapped to different regions of the protein and their ability to neutralize and block virus penetration will be used to identify regions that are of particular functional importance. A cDNA clone of gp85 will be expressed in vaccinia virus to make enough protein for the antibody mapping and to establish the orientation and anchor sequence(s) of the molecule. Virosomes will be used to make artificial "deletion mutants" of gp85 and an effort will be made to obtain quantities of gp85 sufficient to analyze its functions after insertion into liposomes. The second aim is to characterize biochemically and functionally the three novel EBV-induced membrane proteins. One protein will be sequenced and antibodies will be made to synthetic peptides derived from candidate open reading frames to map the other two to the viral genome. the third aim is to use a fusion assay for EBV to examine parameters that influence internalization and to determine the relative importance of different envelope proteins to entry into B cells and epithelial cells.
eb病毒(EBV)是一种普遍存在的人类疱疹病毒

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lindsey M. Hutt-Fletcher其他文献

Lindsey M. Hutt-Fletcher的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Lindsey M. Hutt-Fletcher', 18)}}的其他基金

Anitbody and saliva-mediated enhancement of epithelial cell infection by EBV
抗体和唾液介导的 EBV 上皮细胞感染增强
  • 批准号:
    7487007
  • 财政年份:
    2007
  • 资助金额:
    $ 6.45万
  • 项目类别:
Anitbody and saliva-mediated enhancement of epithelial cell infection by EBV
抗体和唾液介导的 EBV 上皮细胞感染增强
  • 批准号:
    8103016
  • 财政年份:
    2007
  • 资助金额:
    $ 6.45万
  • 项目类别:
Anitbody and saliva-mediated enhancement of epithelial cell infection by EBV
抗体和唾液介导的 EBV 上皮细胞感染增强
  • 批准号:
    7886763
  • 财政年份:
    2007
  • 资助金额:
    $ 6.45万
  • 项目类别:
Anitbody and saliva-mediated enhancement of epithelial cell infection by EBV
抗体和唾液介导的 EBV 上皮细胞感染增强
  • 批准号:
    7655263
  • 财政年份:
    2007
  • 资助金额:
    $ 6.45万
  • 项目类别:
Anitbody and saliva-mediated enhancement of epithelial cell infection by EBV
抗体和唾液介导的 EBV 上皮细胞感染增强
  • 批准号:
    7450235
  • 财政年份:
    2007
  • 资助金额:
    $ 6.45万
  • 项目类别:
EBV Entry and Spread in the Oral Cavity
EBV 进入口腔并传播
  • 批准号:
    6912111
  • 财政年份:
    2005
  • 资助金额:
    $ 6.45万
  • 项目类别:
EBV Entry and Spread in the Oral Cavity
EBV 进入口腔并传播
  • 批准号:
    8510124
  • 财政年份:
    2005
  • 资助金额:
    $ 6.45万
  • 项目类别:
EBV Entry and Spread in the Oral Cavity
EBV 进入口腔并传播
  • 批准号:
    7871395
  • 财政年份:
    2005
  • 资助金额:
    $ 6.45万
  • 项目类别:
Epstein-Barr virus glycoproteins and virus spread
EB 病毒糖蛋白和病毒传播
  • 批准号:
    7557821
  • 财政年份:
    2005
  • 资助金额:
    $ 6.45万
  • 项目类别:
Epstein-Barr virus glycoproteins and virus spread
EB 病毒糖蛋白和病毒传播
  • 批准号:
    6984796
  • 财政年份:
    2005
  • 资助金额:
    $ 6.45万
  • 项目类别:

相似海外基金

Project 4 - Controlling the Latent-to-Lytic Switch in Epstein-Barr Virus
项目 4 - 控制 Epstein-Barr 病毒中的潜伏至裂解转换
  • 批准号:
    10910338
  • 财政年份:
    2023
  • 资助金额:
    $ 6.45万
  • 项目类别:
Epstein-Barr Virus nuclear antigen leader protein in transcription regulation
Epstein-Barr病毒核抗原前导蛋白在转录调控中的作用
  • 批准号:
    10829620
  • 财政年份:
    2023
  • 资助金额:
    $ 6.45万
  • 项目类别:
Exploiting Metabolism to Uncloak Epstein-Barr Virus Immunogens in Latently Infected B-cells
利用代谢揭示潜伏感染 B 细胞中的 Epstein-Barr 病毒免疫原
  • 批准号:
    10889325
  • 财政年份:
    2023
  • 资助金额:
    $ 6.45万
  • 项目类别:
Understanding the immune response changes to clinical interventions for Epstein-Barr virus infection prior to lymphoma development in children after organ transplants (UNEARTH)
了解器官移植后儿童淋巴瘤发展之前针对 Epstein-Barr 病毒感染的临床干预的免疫反应变化(UNEARTH)
  • 批准号:
    10755205
  • 财政年份:
    2023
  • 资助金额:
    $ 6.45万
  • 项目类别:
Regulation and Functions of the Epstein-Barr Virus Lytic Switch Protein
EB 病毒裂解开关蛋白的调控和功能
  • 批准号:
    489085
  • 财政年份:
    2023
  • 资助金额:
    $ 6.45万
  • 项目类别:
    Operating Grants
Characterization of Epstein-Barr Virus Subversion of the Host SMC5/6 Restriction Pathway
Epstein-Barr 病毒颠覆宿主 SMC5/6 限制途径的特征
  • 批准号:
    10679118
  • 财政年份:
    2023
  • 资助金额:
    $ 6.45万
  • 项目类别:
Deciphering the Role of Epstein-Barr Virus Molecular Mimicry and B cell Transformation in Multiple Sclerosis
解读 Epstein-Barr 病毒分子拟态和 B 细胞转化在多发性硬化症中的作用
  • 批准号:
    10568864
  • 财政年份:
    2023
  • 资助金额:
    $ 6.45万
  • 项目类别:
Epstein Barr Virus Driven Mechanisms of Post Transplant Lymphoproliferative Disease
EB 病毒驱动的移植后淋巴增殖性疾病的机制
  • 批准号:
    10755055
  • 财政年份:
    2023
  • 资助金额:
    $ 6.45万
  • 项目类别:
Project 2: Novel investigation of Epstein-Barr virus as a potential cause of conjunctival squamous cell carcinoma among people living with HIV in Zimbabwe
项目 2:对 Epstein-Barr 病毒作为津巴布韦艾滋病毒感染者结膜鳞状细胞癌潜在原因的新调查
  • 批准号:
    10598376
  • 财政年份:
    2023
  • 资助金额:
    $ 6.45万
  • 项目类别:
Project 3 - Characterizing the Amplification Factories of Epstein-Barr Virus and Kaposi's Sarcoma-associated Herpesvirus
项目 3 - 描述 Epstein-Barr 病毒和卡波西肉瘤相关疱疹病毒的扩增工厂
  • 批准号:
    10910337
  • 财政年份:
    2023
  • 资助金额:
    $ 6.45万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了